摘要
目的:分析并鉴定四妙散的化学成分和入血成分,预测其治疗膝骨关节炎(KOA)的药效物质基础和作用机制。方法:采用超高效液相色谱-四级杆-静电场轨道阱质谱联用(UHPLC-QE-MS)技术鉴定四妙散的化学成分及入血成分。根据入血成分进行网络药理学分析,并对核心成分和关键靶点进行分子对接验证。结果:从四妙散水煎剂中共鉴定出354个化学成分。通过比较四妙散水煎剂、空白血清及含药血清样本数据,鉴定出21个入血成分,主要包括黄酮类、萜类、苯丙素类、生物碱类等成分。网络药理学结果表明,四妙散入血成分可能通过调节AKT1、ALB、TNF、EGFR、JUN、SRC、MAPK3等关键靶点,调控PI3K/AKT、Ras、TNF等信号通路发挥治疗KOA效应。分子对接结果显示,四妙散核心入血成分与关键靶点之间具有较好的结合活性。结论:四妙散中黄酮类等入血成分可能通过作用于AKT1等关键靶点,调控PI3K/AKT等关键通路进而发挥治疗KOA效应。
Objective:To systematically analyze and identify the chemical and blood-entry components of Simiao San,predicting its material basis and mechanism in the treatment of knee osteoarthritis(KOA).Method:The chemical and blood-entry components of Simiao San were identified using ultra-high performance liquid chromatography coupled with Q Exactive mass spectrometry(UHPLC-QE-MS).Based on these blood-entry components,network pharmacological analyses were conducted,followed by molecular docking validation of the core components and key targets.Result:A total of 354 chemical components were identified in the water decoction of Simiao San.Comparative analysis of the water decoction,blank serum,and drug-containing serum samples led to the preliminary identification of 21 blood-entry components,predominantly flavonoids,terpenoids,phenylpropanoids,alkaloids,and other compounds.Network pharmacology results indicated that the blood-entry components of Simiao San may exert anti-KOA effects by targeting key proteins such as AKT1,ALB,TNF,EGFR,JUN,SRC,and MAPK3,and modulating pathways including PI3K-AKT,Ras,and TNF.Molecular docking results demonstrated strong binding activity between the core blood-entry components and key targets.Conclusion:The flavonoids and other blood-entry components of Simiao San may exert anti-KOA effects by acting on key targets such as AKT1 and regulating critical pathways like the PI3K-AKT pathway.
作者
伍搏宇
熊辉
杨雷
卢国樑
王海彬
WU Boyu;XIONG Hui;YANG Lei;LU Guoliang;WANG Haibin(The First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou Guangdong 510405,China;The Second Affiliated Hospital of Hunan University of Chinese Medicine,Changsha Hunan 410000,China;Hunan University of Chinese Medicine,Changsha Hunan 410208,China;Dongguan Hospital of Guangzhou University of Chinese Medicine,Dongguan Guangdong 523000,China)
出处
《中医药导报》
2024年第11期15-21,共7页
Guiding Journal of Traditional Chinese Medicine and Pharmacy
基金
湖南省卫生健康委科研计划项目(202204075703)
湖南省教育厅科学研究项目(21A0248)
湖南省中医药科研计划项目(2021002)。